Category Archives: Genotype 1b

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir (Mayret) in Chronic Hepatitis C Patients (SMART-C)

Clinical Trials

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/ Pibrentasvir (Mayret) in Chronic Hepatitis C Patients (SMART-C)

Data has shown that direct-acting antiviral (DAA) regimen of glecaprevir (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor respectively, provides key features for HCV treatment simplification.

Eligible participants (naïve pre-cirrhosis chronic HCV patients) will be randomized (1:2) to the standard or simplified monitoring arm and will receive treatment for 8 weeks.

One post-treatment visit will be conducted 12 weeks after the final dose of study medication to evaluate the proportion of patients with undetectable HCV RNA at this time point (SVR12).

To read about the clinical trial, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Clinical Trials

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

This is a single center study for the donation of HCV-positive livers to HCV negative recipient patients, with preemptive, interventional treatment of Epclusa to prevent HCV transmission upon transplantation.

To view the entire description of the study, click here

 

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

Harvoni Treatment for Porphyria Cutanea Tarda (PCT)

Clinical Trials

In the medical literature, there are case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C

To learn more about this study, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

Anticipated and Perceived Benefits Following Hepatitis C Treatment

Clinical Trials

The study is both qualitative and quantitative, gathering patient’s perceptions of HCV treatment benefits before and after HCV treatment by administering surveys and conducting in-depth qualitative patient interviews. The study seeks to understand all anticipated and actual benefits patients perceive before and after viral eradication.

To read the entire study, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

Multi-Center, Randomized, Open-Label Study of MAVYRET™ (glecaprevir/pibrentasvir) with and without Ribavirin for NS5A + Sofosbuvir Previously Treated Genotype 1 HCV Subjects

Clinical Trials

The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not complete the prescribed duration due to adverse event or any reason other than for non/poor compliance. Subjects will be randomized to 12 or 16 weeks of treatment.

To learn more about this study, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Clinical Trials

Phase 1 of this study will compare the effectiveness of 3 approved HCV treatment regimens to learn whether they work equally well under real-world conditions. Phase 2 of this study will begin early 2017 and will compare the effectiveness of 2 FDA approved HCV treatments. Patients receiving HCV therapy in community and academic clinics will be offered the opportunity to consent to be randomly assigned to one of three regimens and then observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management will be assumed by usual care conditions, and patient-reported outcomes will be collected outside clinic in keeping with pragmatic design principles.

Drug: sofosbuvir/ledipasvir
Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only)
Drug: elbasvir/grazoprevir
Drug: Dasabuvir

To learn more about this study, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment

Clinical Trials

A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1 (a blood test)

To learn more about this study, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

A Study of Mavyret (Glecaprevir (GLE)/Pibrentasvir (PIB)) in Treatment-Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Clinical Trials

Mavyret: A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-naïve adults with chronic HCV GT 1, 2, 4, 5, or 6 infection and compensated cirrhosis.

To learn more about this study, click here

 

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (SMART-C)

Clinical Trials

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (SMART-C)

The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified.  There will be two arms – one arm will have two on-treatment clinic visits; the other arm will have no on-treatment clinic visits.

To read more about this study, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort

Clinical Trials

Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort

This is a multicentre, descriptive, observational and ambispective (also known as a historical prospective) study carried out in patients who are treated with Zepatier (Elbasvir/Grazoprevir) in hospitals that included their data in Hepa-C Registry (directed by the Spanish Association for the Study of the Liver and the Networked Biomedical Research Centre for Hepatic and Digestive Diseases).

To read more about the study, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter